The Hims & Hers advertisement, set to air during the Super Bowl, approaches the obesity crisis with a critical lens on the weight-loss industry, valued at $160 billion. It suggests a solution via weight-loss drugs but fails to disclose risks associated with compounded medications, which have not undergone standard FDA approval. The ad has been met with backlash from U.S. senators and healthcare professionals who are concerned it mislead patients, prompting calls for increased transparency regarding side effects and drug safety.
The advert highlights America's obesity crisis and critiques the $160 billion weight-loss industry, advocating for weight-loss medications while neglecting critical safety disclosures.
The ad claims to present a solution to obesity through weight-loss drugs, yet significantly downplays the concerns surrounding their approval and safety.
Lawmakers and medical professionals have criticized the ad for misleading patients about obesity medications, emphasizing the absence of standard risk disclosures.
The Partnership for Safe Medicines voiced concerns that the ad promotes compounded drugs without sufficient warnings, calling for its retraction due to safety risks.
Collection
[
|
...
]